Javier Cortés

Research interests

Publications

• Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

  Journal of Clinical Oncology · 2024 · https://doi.org/10.1200/jco.23.01994

• ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.05.008

• Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2214131

• Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)02420-5

• Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.22.00338

• Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2202809

• Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.015

• Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2028485

• ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.019

• Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

  JAMA Oncology · 2021 · https://doi.org/10.1001/jamaoncol.2020.7932

• Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30754-3

• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

  The Lancet · 2020 · 10.1016/s0140-6736(20)32531-9

• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30863-0

• Pembrolizumab for Early Triple-Negative Breast Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1910549

• HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

  JNCI Journal of the National Cancer Institute · 2019 · https://doi.org/10.1093/jnci/djz042

• Breast cancer

  Nature Reviews Disease Primers · 2019 · https://doi.org/10.1038/s41572-019-0111-2

• Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1914510

• Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.00368

• nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy201

• Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

  European Journal of Cancer · 2017 · https://doi.org/10.1016/j.ejca.2017.10.021

• Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

  Cancer Research · 2016 · https://doi.org/10.1158/0008-5472.can-15-0728

• Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

  Nature Communications · 2015 · 10.1038/ncomms9839

• Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00373-3

• Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1413513

• The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

  Nature Genetics · 2015 · https://doi.org/10.1038/ng.3218

• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

  The Lancet Oncology · 2013 · https://doi.org/10.1016/s1470-2045(13)70130-x

• Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt182

• Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds586

• Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1113216

• Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2008.21.6457

Current projects

No projects listed.